Variable | IAE (n = 40) | IANE (n = 32) | Χ2/t/U | P* |
Male/Female | 26/14 | 20/12 | 0.048 | 0.826 |
Age/Month | 58 (23, 97) | 60 (35, 84) | 437.000 | 0.545 |
Blood biochemical | ||||
AST/U·L−1 | 37 (33, 47) | 49 (35, 101) | 815.000 | 0.026 |
ALT/U·L−1 | 18 (12, 20) | 25 (14, 48) | 776.500 | 0.013 |
CK/U·L−1 | 174 (115, 279) | 239 (159, 356) | 440.000 | 0.036 |
CK-MB/U·L−1 | 15 (9, 26) | 19 (12, 33) | 347.000 | 0.105 |
Cr/umol·L−1 | 32 (24, 38) | 41 (23, 49) | 1842.000 | 0.689 |
Urea/mmol·L−1 | 3.39 (3.06, 4.40) | 3.78 (3.10, 5.30) | 655.000 | 0.164 |
LDH/U·L−1 | 336 (218, 493) | 567 (369, 916) | 109.500 | <0.001 |
Coagulation | ||||
PT/S | 14.66 ± 1.08 | 16.79 ± 5.21 | 1.514 | 0.153 |
TT/S | 17.47 ± 1.76 | 19.58 ± 4.29 | 1.773 | 0.096 |
APTT/S | 45.97 ± 14.39 | 49.45 ± 10.82 | 0.651 | 0.522 |
FIB/g·L−1 | 3.05 ± 0.88 | 2.63 ± 0.92 | 1.444 | 0.156 |
Cerebrospinal fluid | ||||
CSF leukocyte /106·L−1 | 3 (1, 4) | 4 (1, 6) | 326.000 | 0.094 |
CSF GLU/mmol·L−1 | 3.44 (3.20, 3.67) | 3.71 (3.17, 4.27) | 356.000 | 0.231 |
CSF LDH/U·L−1 | 21 (16, 24) | 76 (24, 145) | 127.500 | <0.001 |
CSF PRO/g·L−1 | 0.28 (0.21, 0.39) | 0.65 (0.43, 0.98) | 147.000 | <0.001 |
The prognosis | ||||
Sequelae (%) | 14 (35) | 17 (53) | 2.382 | 0.123 |
Died (%) | 0 (0) | 10 (31) | 12.021 | 0.001 |